Pharmaceuticals - Turkey

Turkey

In 2024, the projected revenue in the Pharmaceuticals market in Turkey is expected to reach US$2,094.00m.
Among the various markets, the largest one is Oncology Drugs, with a projected market volume of US$326.50m in 2024.
Looking ahead, the revenue is anticipated to exhibit an annual growth rate of 3.86% (CAGR 2024-2029), resulting in a market volume of US$2,530.00m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Pharmaceuticals market, with an estimated amount of US$630.30bn in 2024.
Turkey's pharmaceutical market is experiencing a surge in demand for generic drugs due to their affordability and availability.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Turkey has been experiencing significant growth in recent years, driven by various factors that are unique to the country.

Customer preferences: Turkey has a large and growing population, with an increasing demand for healthcare services and products. The country has a universal healthcare system that provides free or low-cost healthcare to all citizens. However, many people still prefer to use private healthcare services, which has led to a growing demand for pharmaceutical products. In addition, there is a growing trend towards self-medication, with many people choosing to purchase over-the-counter drugs for minor ailments.

Trends in the market: One of the key trends in the Turkish pharmaceuticals market is the increasing focus on research and development. Many local companies are investing heavily in R&D to develop new drugs and treatments, while multinational companies are also expanding their operations in the country. Another trend is the growing demand for generic drugs, which are cheaper than branded products and are becoming increasingly popular among consumers. Finally, there is a trend towards consolidation in the market, with many smaller companies being acquired by larger players.

Local special circumstances: One of the unique factors that is driving growth in the Turkish pharmaceuticals market is the country's strategic location. Turkey is situated at the crossroads of Europe and Asia, making it an important hub for pharmaceutical companies looking to expand their operations in these regions. In addition, the Turkish government has implemented a number of policies aimed at promoting the development of the local pharmaceutical industry, including tax incentives and subsidies for R&D.

Underlying macroeconomic factors: The Turkish economy has been growing steadily in recent years, with a strong focus on exports and foreign investment. This has led to increased demand for healthcare services and products, including pharmaceuticals. In addition, the country's large and growing population, coupled with a growing middle class, has created a significant market for pharmaceutical companies. Finally, the Turkish government's focus on healthcare reform and investment in the sector is also driving growth in the pharmaceuticals market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.